Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening
Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Feb 20, 2025
Trial Information
Current as of July 06, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new AI-assisted diagnostic tool called VeriSee, which helps doctors diagnose common eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma. The technology uses special photographs of the inside of the eye to quickly analyze images and provide results that doctors can use to make informed decisions about diagnosis and treatment. The goal is to improve the speed and accuracy of eye disease screenings, ultimately benefiting patients.
To participate in this trial, you need to be in one of the following groups: adults aged 50 and older for AMD screenings, diabetic patients aged 20 and older for DR screenings, or adults aged 20 and older with mild nearsightedness for glaucoma screenings. The trial is not yet recruiting participants, but if you are eligible and choose to participate, you will undergo screening with the AI system, and your results will help researchers understand how effective this technology is in real-world settings. Remember, your participation is voluntary, and you must agree to take part in the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above.
- • VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above.
- Exclusion Criteria:
- • The patient does not agree to participate in the trial or is unable to provide informed consent.
About National Taiwan University Hospital
National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported